Amylyx Pharmaceuticals, Inc.
13.89-0.43 (-3%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · AMLX · USD
Key Stats
Market Cap
1.48BP/E (TTM)
-Basic EPS (TTM)
-2.49Dividend Yield
0%Recent Filings
8-K
Amylyx launches $164M stock offering
Amylyx Pharmaceuticals entered an underwriting agreement on September 9, 2025, to sell 17.5 million shares of common stock at $10.00 each, expecting net proceeds of $164.0 million—or $188.7 million if underwriters exercise their 30-day option for 2.625 million more shares—with closure anticipated September 11, 2025. Funds will advance avexitide's commercial readiness alongside research, development, and general corporate needs. Yet risks loom: the deal hinges on customary conditions.
8-K
Amylyx halts PSP drug program
Amylyx Pharmaceuticals discontinued its ORION program for AMX0035 in progressive supranuclear palsy patients after the Phase 2b trial failed to show differences versus placebo on primary or secondary outcomes at Week 24. The company will halt the open-label extension and skip the planned Phase 3. Safety remained consistent with prior studies. This setback narrows Amylyx's pipeline focus.
10-Q
Q2 FY2025 results
Amylyx Pharmaceuticals narrowed its Q2 net loss to $41.4M from $72.7M a year earlier, thanks to a 43% drop in operating expenses to $42.9M, driven by restructuring cuts and lower SG&A after pulling RELYVRIO from the market. R&D climbed 17% y/y to $27.2M, fueled by the Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia, while no revenue was recorded, matching the prior quarter's zero. Cash and equivalents dipped to $58.1M from $77.4M at year-end, bolstered by $65.6M from a January equity raise, yielding $180.8M in total liquidity. No debt weighs on the balance sheet. Pipeline progress shines, but regulatory hurdles loom large.
8-K
Amylyx Q2 loss narrows
Amylyx Pharmaceuticals reported a Q2 2025 net loss of $41.4 million, or $0.46 per share, improved from $72.7 million last year, with R&D expenses up to $27.2 million on pipeline advances while SG&A fell to $15.6 million. Cash stood at $180.8 million, funding operations through 2026. Recruitment for the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia nears completion this year, topline data due H1 2026. Pipeline momentum builds, yet clinical risks loom.
8-K
Annual meeting elects directors
Amylyx Pharmaceuticals held its annual stockholder meeting on June 5, 2025, electing Karen Firestone, Justin Klee, and Bernhardt Zeiher as Class I directors for three-year terms. Stockholders ratified Deloitte & Touche LLP as auditors for 2025, with overwhelming support. The advisory vote on executive compensation passed narrowly, 33 million for versus 24 million against. Board continuity holds firm.
AGIO
Agios Pharmaceuticals, Inc.
41.96-1.47
ALZN
Alzamend Neuro, Inc.
2.45+0.09
ATHA
Athira Pharma, Inc.
4.08-0.13
AVXL
Anavex Life Sciences Corp.
8.02-0.08
IMMX
Immix Biopharma, Inc.
3.72-0.18
LXRX
Lexicon Pharmaceuticals, Inc.
1.33-0.04
MBRX
Moleculin Biotech, Inc.
0.48-0.00
MBX
MBX Biosciences, Inc.
19.52+1.56
NRSN
NeuroSense Therapeutics Ltd.
1.06-0.06
NRXP
NRX Pharmaceuticals, Inc.
3.05+0.05